Mei Yanhui, Zheng Jianbo, Xiang Ping, Liu Cheng, Fan Yidong
Department of Urology, Qilu Hospital of Shandong University, Jinan.
Department of Urology, Binzhou Medical University Hospital, Binzhou.
Medicine (Baltimore). 2020 Nov 20;99(47):e22891. doi: 10.1097/MD.0000000000022891.
We aimed to evaluate the prognostic significance of high expression of the miR-200 family of microRNAs in bladder cancer.
Studies on the correlation between the miR-200 family and prognosis in patients with bladder cancer were searched in databases. Combined hazard ratios (HRs) were calculated based on HRs and 95% confidence intervals (CIs) for overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Cochranes Q test and the I statistic were utilized to assess heterogeneity across the included studies. Potential publication bias was analyzed by Begg and Egger tests. The meta-analysis was conducted using RevMan 5.3 and Stata SE12.0.
Data from a total of 1150 patients from 8 studies were extracted. The meta-analysis revealed that high expression of the miR-200 family was correlated with better OS (pooled hazard ratio: 0.50, 95% confidence interval: 0.40-0.62), CSS (pooled hazard ratio: 0.36, 95% confidence interval: 0.22-0.59) and RFS (pooled hazard ratio: 0.48, 95% confidence interval: 0.36-0.65). Both Begg test and Egger test verified no publication bias within the included cohorts.
The high expression of the miR-200 family is strongly associated with better prognosis in bladder cancer patients, which will improve bladder cancer management in clinical practice.
我们旨在评估微小RNA miR-200家族高表达在膀胱癌中的预后意义。
在数据库中检索关于miR-200家族与膀胱癌患者预后相关性的研究。基于总生存（OS）、癌症特异性生存（CSS）和无复发生存（RFS）的风险比（HRs）及95%置信区间（CIs）计算合并风险比。采用Cochrane Q检验和I统计量评估纳入研究间的异质性。通过Begg检验和Egger检验分析潜在的发表偏倚。使用RevMan 5.3和Stata SE12.0进行荟萃分析。
从8项研究中提取了总共1150例患者的数据。荟萃分析显示，miR-200家族高表达与更好的OS（合并风险比：0.50，95%置信区间：0.40 - 0.62）、CSS（合并风险比：0.36，95%置信区间：0.22 - 0.59）和RFS（合并风险比：0.48，95%置信区间：0.36 - 0.65）相关。Begg检验和Egger检验均证实纳入队列中无发表偏倚。
miR-200家族高表达与膀胱癌患者更好的预后密切相关，这将改善临床实践中膀胱癌的管理。
